During Thursday’s trading session, the shares of a company engaged in the supply of pharmaceutical products surged 2.6 percent to Rs. 188.28 on NSE, after the Board of the company fixed the record date for a 1:5 stock split as well as a 1:1 bonus issue.
With a market capitalisation of Rs. 198.2 crores, the shares of Vaishali Pharma Limited closed in the green at Rs. 184.9, up by 0.74 percent, as against its previous closing price of Rs. 183.54.
What’s the News:
According to the latest regulatory filings with the NSE, the Board of Vaishali Pharma Limited has fixed 15th October as the Record date for the purpose of sub-division of the equity shares as well as the issue of bonus shares.
The Board of Directors at its meeting held on 28th August approved the proposal of a stock split in a 1:5 ratio, which means that every 1 equity share having a face value of Rs. 10 each will be divided into 5 equity share having a face value of Rs. 2 each.
Further, the Board also approved the Bonus Shares in a 1:1 ratio, which means that the shareholders will receive 1 new bonus equity share of the face value of Rs. 2, for every 1 existing equity share held.
Financials:
The company reported a significant growth in revenue from operations, experiencing a year-on-year increase of nearly 35 percent, rising from Rs. 13.4 crores in Q1 FY24 to Rs. 18.08 crores in Q1 FY25.
During the same period, the company’s net profit rose marginally from Rs. 1.6 crores to Rs. 1.7 crores, representing a growth of around 6.3 percent YoY.
In terms of return ratios, Vaishali Pharma reported a return on equity (RoE) of 1.73 percent, and a return on capital employed (RoCE) of 5.72 percent. Additionally, the company’s debt-to-equity ratio stands at 0.31.
Stock Performance
The stock has delivered positive returns of nearly 32.2 percent of returns in one year, as well as around 22 percent returns in the last six months. However, so far in 2024, the shares of Vaishali Pharma have given negative returns of about 1 percent.
About the Company:
Incorporated in 2008, Vaishali Pharma Limited is primarily engaged in the marketing of a diverse range of pharmaceutical products including active pharmaceutical ingredients (APIs), formulations, surgical products, veterinary supplements, herbal items, nutraceuticals, and oncology products. Their portfolio serves both human and animal healthcare needs.
With a domestic presence in Maharashtra, the company has expanded globally through partnerships in the Democratic Republic of Congo, Kenya, and Russia.
Written by Shivani Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
